section name header

Pronunciation

PIN-doe-lole

Classifications

Therapeutic Classification: antihypertensives

Pharmacologic Classification: beta blockers

Indications

REMS


Unlabeled Use:
  • Management of angina pectoris.

Action

  • Blocks stimulation of beta1 (myocardial) and beta2 (pulmonary, vascular, and uterine) -adrenergic receptor sites.
  • Has intrinsic sympathomimetic activity (ISA), which may produce less bradycardia.
Therapeutic effects:
  • Decreased heart rate and BP.

Pharmacokinetics

Absorption: Well absorbed following oral administration.

Distribution: Moderate CNS penetration. Crosses the placenta; enters breast milk.

Metabolism/Excretion: Partially metabolized by the liver; 50% excreted unchanged by the kidneys.

Half-Life: 3–4 hr.

Time/Action Profile

(cardiovascular effects)

ROUTEONSETPEAKDURATION
PO7 days2 wk8–24 hr





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: HF, ARRHYTHMIAS, BRADYCARDIA, orthostatic hypotension, peripheral vasoconstriction, PULMONARY EDEMA

Derm: itching, rashes

EENT: blurred vision, dry eyes, nasal stuffiness

Endo: hyperglycemia, hypoglycemia

GI: constipation, diarrhea, nausea

GU: erectile dysfunction, libido

MS: arthralgia, back pain, muscle cramps

Neuro: fatigue, weakness, anxiety, depression, dizziness, drowsiness, insomnia, memory loss, mental status changes, nervousness, nightmares, paresthesia

Resp: bronchospasm, wheezing

Misc: drug-induced lupus syndrome

Interactions

Drug-drug:

Route/Dosage

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Visken

Canadian Brand Names

Visken